Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.10.0.1
Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 6 Months Ended
Dec. 13, 2017
Aug. 04, 2016
Jun. 15, 2012
Jun. 30, 2018
Jun. 30, 2017
Feb. 16, 2016
George Clinical Services [Member]            
Commitments and Contingencies (Textual)            
Project estimated cost   $ 4,600,000        
Research and development costs       $ 700,000 $ 200,000  
Goodwin [Member]            
Commitments and Contingencies (Textual)            
Research and development costs       800,000 300,000  
Project remaining cost       1,500,000    
Fred Hutchinson Cancer Research Center (FHCRC) [Member] | License and Sponsored Research Agreement [Member]            
Commitments and Contingencies (Textual)            
Milestones Payments     $ 1,000,000      
Description of royalty payment     Royalty payments of 2% of net sales will be due to FHCRC.      
Incurred expenses       0 44,000  
Oak Ridge National Laboratory (ORNL) [Member]            
Commitments and Contingencies (Textual)            
Purchase of materials $ 200,000     100,000 300,000  
Medpace Inc [Member]            
Commitments and Contingencies (Textual)            
Total project estimated to cost           $ 7,200,000
Research and development costs       $ 1,500,000 1,400,000  
Memorial Sloan Kettering Cancer Center [Member]            
Commitments and Contingencies (Textual)            
Royalty, description      

Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.

   
Maintenance fees and research cost       $ 100,000 $ 100,000